G1 Therapeutics buy HC Wainwright
Start price
25.06.24
/
50%
€2.06
Target price
25.06.25
€2.80
Performance (%)
212.68%
End price
26.06.25
-
Summary
This prediction is currently being closed. With a performance of 212.68% the BUY prediction by HC_Wainwright is a big success. HC_Wainwright has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| G1 Therapeutics | - | - | - |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% |
Comments by HC_Wainwright for this prediction
In the thread G1 Therapeutics diskutieren
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at HC Wainwright from $9.00 to $3.00. They now have a "buy" rating on the stock.
Ratings data for GTHX provided by MarketBeat
In the thread Trading G1 Therapeutics
Die von HC_Wainwright gewählte maximale Laufzeit wurde überschritten